A new systematic review published in the journal eClinicalMedicine on Wednesday examined 48 studies that analyzed and predicted the outcomes of people who either had diabetes or were overweight or obese and took popular GLP-1 medications such as liraglutide (under brand names such as Victoza and Saxenda), semaglutide (under brand names such as Ozempic, Wegovy, Rybelsus) and tirzepatide (under brand names like Mounjaro and Zepbound)
These changes to GLP-1 were not significantly different between T-RDN and A-RDN in both HF and Sham groups
Lee SJ, Sanchez-Watts G, Krieger JP, Pignalosa A, Norell PN, Cortella A, et al
I thought with all the AI ads that this was going to be a scam
If you want a bigger picture of how GLP-1 fits into weight loss, you can read our main guide here: GLP-1 for Weight Loss: Simple Guide for Beginners 6